INTRODUCTION
============

In the time since the first successful application of extracorporeal membrane oxygenation (ECMO) support in 1972 ([@B1]), ECMO has become one of the most important therapeutic modalities for severe cardiopulmonary failure ([@B2]). The use of ECMO to treat adults has increased greatly since the H1N1 influenza pandemic of 2009 and publication of the findings of a multicenter randomized trial of treatments for severe adult respiratory failure (the CESAR trial) ([@B3][@B4]).

Although the experience of clinicians with ECMO therapy in adult populations is growing, ECMO is still associated with high-level mortality and many potential complications. Of these, nosocomial infection (NI) is associated with high-level mortality ([@B5][@B6]). Adult patients undergoing ECMO are at higher risk for nosocomial infection than neonate and pediatric patients (6.1% of neonates and pediatric patients vs. 20.5% of adults develop culture-proven infections during ECMO) ([@B5]).

However, data on NIs acquired during ECMO in the adult populations remain scarce. Although a few studies have explored this topic ([@B7][@B8]), the works have been limited in terms of patient numbers considerable heterogeneity in patient baseline characteristics including the ECMO mode employed (venovenous vs. venoarterial), the indications for ECMO, and the ECMO cannulation site (percutaneous vs. intrathoracic). Such heterogeneity may affect the incidence of NI development during ECMO. Thus, further work with a homogeneous patient group is required to precisely identify risk factors for NI in patients on ECMO support.

Therefore, we investigated the risk factors for NIs in patients with cardiogenic shock who underwent percutaneous venoarterial ECMO (VA-ECMO) support.

MATERIALS AND METHODS
=====================

Patients
--------

From January 2011 to December 2015, 259 consecutive patients underwent ECMO at Chonnam National University Hospital. Patients aged 17 years or less were excluded. Patients who underwent ECMO for \< 48 hours were not included in this study since they were not exposed to ECMO long enough to identify ECMO-related infection events. A total of 95 adult patients underwent VA-ECMO for cardiogenic shock. Of these, 34 adult patients underwent ECMO support for \< 48 hours. Among the 34 patients, 2 patients survived and 32 patients were non-survivors. The cause of death in the 32 non-survivor patients included hypoxic brain death in 8 patients and multi-organ failure in 24. However, there was no sepsis-related death in these patients. Finally, cardiogenic shock patients (n = 61) undergoing ECMO for ≥ 48 hours were evaluated. Weaning success rate, survival to discharge, and infection incidence on ECMO were assessed through hospital records. Baseline characteristics and operative information including age, gender, underlying conditions, pre-ECMO laboratory findings, Sequential Organ Failure Assessment (SOFA) score, chest X-ray state (1 point per quadrant infiltrated) before ECMO, transfusion history before ECMO, hospital and intensive care unit (ICU) stay before ECMO, type and mode of ECMO, type of anticoagulation, and duration of ECMO support were collected and evaluated. Each patient\'s survival at the time of ECMO de-cannulation and at the time of discharge was also evaluated in terms of weaning success rate and survival to discharge.

ECMO procedures
---------------

Cannulation of ECMO was performed in a sterile fashion with chlorhexidine painting. In ECMO-eligible patients, an emergency bypass system (n = 38, 62.3%; Terumo Inc., Tokyo, Japan) or a permanent life support system (n = 23, 37.7%; Maquet Inc., Hirrlingen, Germany) was applied. The oxygenator of the permanent life support system is a polymethylpentene (PMP) type. The emergency bypass system is a non-PMP type oxygenator. Recently, the Maquet system has been more commonly used than the Terumo system, which is known to be the more durable and thrombo-resistant device ([@B9]). Heparin or nafamostat mesilate was used as an anticoagulant. Cannulation mode, size, and approach site were determined by the surgeon considering the patient\'s body weight, height, and vessel size. A peripheral approach using femoral artery and vein was the predominant approach in the study. The management protocol for ECMO follows the Extracorporeal Life Support Organization (ELSO) guidelines ([@B10]).

Definition of nosocomial infection during ECMO support
------------------------------------------------------

The definition of nosocomial infections during ECMO support was based on the Centers for Disease Control and Prevention definitions for nosocomial infections ([@B11]). Nosocomial infection during ECMO support was defined as a case with confirmed organisms from one or more blood, respiratory, or urinary cultures during the period 48 hours after the initiation of ECMO to 24 hours after ECMO weaning. Microbiological isolations were correlated with clinical symptoms and typical inflammatory characteristics in blood samples and radiographic findings.

Antibiotics strategy
--------------------

Prophylactic antibiotics with broad spectrum drug was prescribed to patients at the initiation of ECMO support. In patients who had already been taking antibiotics, antibiotic agents were maintained. If infection developed during ECMO support, antibiotics were changed according to the culture results. With regard to dosing of antibiotics, conventional dose was started and adjusted according to the drug concentration monitoring. Every antibiotic therapy was discussed with the department of infection and adjusted according to the patient\'s clinical situations.

Statistical analysis
--------------------

Categorical variables are presented as frequencies and percentages and continuous variables are expressed as means ± standard deviations. Student\'s t-tests and χ^2^ tests were used to compare factors related to nosocomial infection. We performed the logistic regression using nosocomial infection as the dependent variable. *P* values \< 0.05 were considered statistically significant. SPSS version 24.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

Ethics statement
----------------

This study was approved by Institutional Review Board of Chonnam National University Hospital, which waived the requirement for informed patient consent based on the retrospective nature of the work (IRB No: CNUH-2016-228).

RESULTS
=======

Baseline characteristics
------------------------

The 61 patients with cardiogenic shock underwent ECMO for a total of 416.0 days. The mean age of patients at the time of ECMO support was 60.6 ± 14.3 years, and 34.4% (n = 21) were female. A total of 42.6% (n = 26) of patients had hypertension and 41.0% (n = 25) diabetes mellitus. The infiltration status of pre-ECMO chest X-rays was 1.6 ± 1.4. Eighteen patients (29.5%) had a transfusion history before ECMO. Pre-ECMO hospital and ICU stays before ECMO were 4.4 ± 6.5 and 1.8 ± 2.5 days, respectively ([Table 1](#T1){ref-type="table"}). Venoarterial type was the predominant ECMO type in 95.1% (n = 58) of the patients. Venoarterial-venous type of ECMO was applied in 3 patients (4.9%). According to the ECMO oxygenator type, the non-PMP oxygenator was used in 38 patients (62.3%) and the PMP type in 23 patients (37.7%). Anticoagulation was performed using heparin in 88.6% (n = 54) of patients. The duration of ECMO support was 6.8 ± 7.4 days ([Table 2](#T2){ref-type="table"}).

###### Baseline characteristics before ECMO support
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  Characteristics                   Value^\*^
  --------------------------------- --------------
  No. of patients                   61
  Age, yr                           60.6 ± 14.3
  Female gender                     21 (34.4)
  Body weight, kg                   62.1 ± 11.8
  Underlying condition              
   Hypertension                     26 (42.6)
   Diabetes mellitus                25 (41.0)
   Coronary artery disease          10 (16.4)
   Chronic renal disease            5 (8.2)
   Acute kidney injury              3 (4.9)
   Dialysis                         3 (4.9)
   COPD                             1 (1.6)
   Cerebrovascular accident         2 (3.3)
  Laboratory findings               
   White blood cell (10^3^/mm^3^)   12.8 ± 5.9
   Hemoglobin, g/dL                 11.9 ± 2.8
   Platelets (10^3^/mm^3^)          204.7 ± 77.8
   CRP, mg/dL                       4.6 ± 6.2
   Lactate, mmol/L                  8.9 ± 4.7
   Total bilirubin, mg/dL           1.1 ± 0.9
   Creatinine, mg/dL                1.5 ± 1.2
  SOFA score                        8.6 ± 2.2
  Infiltration status on CXR^†^     1.6 ± 1.4
  Transfusion history               18 (29.5)
  Pre-ECMO ICU stay, day            1.8 ± 2.5
  Pre-ECMO hospital stay, day       4.4 ± 6.5

ECMO = extracorporeal membrane oxygenation, COPD = chronic obstructive lung disease, CXR = chest X-ray, CRP = C-reactive protein, ICU = intensive care unit, SOFA = Sequential Organ Failure Assessment.

^\*^Data are presented as numbers of cases (%) for categorical variables or as means ± standard deviations for continuous variables; ^†^One point for each quadrant infiltrated (0--4).

###### ECMO data of patients
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  Parameters of ECMO              Value^\*^
  ------------------------------- -----------
  No. of patients                 61
  ECMO support                    
   Venoarterial mode              58 (95.1)
   Venoarterial-venous mode       3 (4.9)
  Type of ECMO oxygenator         
   Non-PMP membrane               38 (62.3)
   PMP membrane                   23 (37.7)
  Anticoagulation drug used       
   Heparin                        54 (88.6)
   Nafamostat mesilate            7 (11.4)
  Duration of ECMO support, day   6.8 ± 7.4

ECMO = extracorporeal membrane oxygenation, PMP = polymethylpentene.

^\*^Data are presented as numbers of cases (%) for categorical variables or as means ± standard deviations for continuous variables.

Early outcomes and infection incidence
--------------------------------------

The rates of weaning success and survival to discharge were 44.3% (27/61) and 31.1% (19/61), respectively. There were 18 nosocomial infection events of 14 (23.0%) patients. The incidence of ECMO-related nosocomial infection was 43.3 cases per 1,000 ECMO-days. These included bloodstream infection (BSI) in 9 cases, and respiratory tract infection (RTI) in 9 cases ([Table 3](#T3){ref-type="table"}). However, there was no urinary tract infection (UTI) and surgical site wound infection.

###### Microorganisms causing infections during ECMO support
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  Microorganism species           RTI (n = 9)   BSI (n = 9)
  ------------------------------- ------------- -------------
  Gram-negative pathogens                       
   *A. baumannii*                 8             2
   *P. aeruginosa*                0             2
   *Enterobacter cloacae*         0             0
   *Serratia marcescens*          0             1
   *Klebsiella pneumonia*         0             1
  Gram-positive pathogens                       
   *S. aureus*                    0             1
   *Staphylococcus epidermidis*   0             1
   *Corynebacterium striatum*     0             1
  Fungi                                         
   *Candida albicans*             1             0
   *Candida tropicalis*           0             0

ECMO = extracorporeal membrane oxygenation, RTI = respiratory tract infection, BSI = bloodstream infection.

Causative microorganisms of nosocomial infection
------------------------------------------------

The offending organisms associated with nosocomial infection are shown in [Table 3](#T3){ref-type="table"}. Gram-negative pathogens were predominant in both RTI and BSI. *Acinetobacter baumannii* (n = 8, 88.9%) was the most common respiratory tract pathogens. In terms of BSI, *A. baumannii* (n = 2), and *Pseudomonas aeruginosa* (n = 2) were the most common pathogens.

The characteristics and ECMO outcomes of patients with and without nosocomial infections
----------------------------------------------------------------------------------------

The baseline characteristic data for 47 patients without nosocomial infection and 14 patients with nosocomial infection are shown in [Tables 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. There were no significant differences between the 2 groups in terms of age, sex, body weight, underlying condition, laboratory findings, infiltration state in chest X-ray, ICU and hospital stay before ECMO, ECMO oxygenator type and anticoagulation drug type. However, patients with nosocomial infection underwent ECMO for a longer period than patients without nosocomial infection (14.5 ± 12.4 days vs. 4.5 ± 2.4 days, *P* = 0.010). The rates of weaning success and survival to discharge were higher in patients without nosocomial infection than in patients with nosocomial infection, (48.9% vs. 28.6% and 36.2% vs. 14.3%, respectively); however, the differences were not significant (*P* = 0.228 and *P* = 0.190, respectively).

###### The characteristics of patients with and without nosocomial infections during ECMO
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  Risk factors                      Without infection^\*^(n = 47)   With infection^\*^(n = 14)   *P* value
  --------------------------------- ------------------------------- ---------------------------- -----------
  Age, yr                           61.3 ± 14.9                     58.5 ± 12.5                  0.529
  Female gender                     14 (29.8)                       7 (50.0)                     0.206
  Body weight, kg                   62.9 ± 12.1                     59.6 ± 10.5                  0.369
  Underlying condition                                                                           
   Hypertension                     19 (40.4)                       7 (50.0)                     0.553
   Diabetes mellitus                18 (38.3)                       7 (50.0)                     0.540
   Coronary artery disease          7 (14.9)                        3 (21.4)                     0.683
   Chronic renal disease            3 (6.4)                         2 (14.3)                     0.322
   Acute kidney injury              3 (6.4)                         0                            \> 0.999
   Dialysis                         2 (4.3)                         1 (7.1)                      0.549
   COPD                             0                               1 (7.1)                      0.230
   Cerebrovascular accident         2 (4.3)                         0                            \> 0.999
  Laboratory findings                                                                            
   White blood cell (10^3^/mm^3^)   12.5 ± 6.1                      13.7 ± 5.2                   0.490
   Hemoglobin, g/dL                 12.1 ± 2.8                      11.2 ± 3.0                   0.310
   Platelets (10^3^/mm^3^)          204.8 ± 82.2                    204.4 ± 63.5                 0.989
   CRP, mg/dL                       4.8 ± 6.6                       3.7 ± 5.1                    0.563
   Lactate, mmol/L                  8.7 ± 4.4                       9.7 ± 5.7                    0.499
   Total bilirubin, mg/dL           1.1 ± 0.9                       1.1 ± 1.1                    0.819
   Creatinine, mg/dL                1.4 ± 0.8                       2.1 ± 2.1                    0.227
  SOFA score                        8.5 ± 2.4                       9.0 ± 1.7                    0.473
  Infiltration status on CXR        1.6 ± 1.4                       1.6 ± 1.6                    0.874
  Peak body temperature, ℃          37.3 ± 1.3                      37.2 ± 1.0                   0.667
  Transfusion history               17 (36.2)                       1 (7.1)                      0.047
  Pre-ECMO ICU stay, day            1.7 ± 2.0                       2.1 ± 3.7                    0.599
  Pre-ECMO hospital stay, day       4.5 ± 7.0                       3.9 ± 4.3                    0.747

ECMO = extracorporeal membrane oxygenation, COPD = chronic obstructive lung disease, CRP = C-reactive protein, CXR = chest X-ray, ICU = intensive care unit, SOFA = Sequential Organ Failure Assessment.

^\*^Data are presented as numbers of cases (%) for categorical variables or as mean ± standard deviation for continuous variables.

###### Outcomes of ECMO support in patients with and without nosocomial infections

![](jkms-32-593-i005)

  Outcomes                     Without infection^\*^ (n = 47)   With infection^\*^ (n = 14)   *P* value
  ---------------------------- -------------------------------- ----------------------------- -----------
  ECMO oxygenator type                                                                        0.756
   Non-PMP membrane            30 (63.8)                        8 (57.1)                      
   PMP membrane                17 (36.2)                        6 (42.9)                      
  Anticoagulation drug given                                                                  0.710
   Heparin                     42 (89.3)                        12 (85.7)                     
   Nafamostat mesilate         5 (10.7)                         2 (14.3)                      
  ECMO support duration, day   4.5 ± 2.4                        14.5 ± 12.4                   0.010
  ECMO weaning                                                                                0.228
   Success                     23 (48.9)                        4 (28.6)                      
   Failure                     24 (51.1)                        10 (71.4)                     
  Survival to discharge                                                                       0.190
   Yes                         17 (36.2)                        2 (14.3)                      
   No                          30 (63.8)                        12 (85.7)                     

ECMO = extracorporeal membrane oxygenation, PMP = polymethylpentene.

^\*^Data are presented as numbers of cases (%) for categorical variables or as means ± standard deviations for continuous variables.

Multivariate analysis of risk factors for nosocomial infection
--------------------------------------------------------------

In the logistic regression analysis, pre-specified covariates were included in this analysis. Independent predictors of infection during ECMO were a higher preoperative creatinine level (adjusted odds ratio \[OR\], 2.176; 95% confidence interval \[CI\], 1.065--4.447; *P* = 0.033) and the duration of ECMO support (adjusted OR, 1.400; 95% CI, 1.081--1.815; *P* = 0.011) ([Table 6](#T6){ref-type="table"}). [Fig. 1](#F1){ref-type="fig"} shows the incidence of infection according to the duration of ECMO.

###### Multivariate analysis of risk factors for nosocomial infection
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  Variables                          Adjusted OR (95% CI)   *P* value
  ---------------------------------- ---------------------- -----------
  Pre-ECMO creatinine level, mg/dL   2.176 (1.065--4.447)   0.033
  Duration of ECMO support, day      1.400 (1.081--1.815)   0.011

OR = odds ratio, CI = confidence interval, ECMO = extracorporeal membrane oxygenation.

^\*^Variables with a probability valve \< 0.20 in univariate analyses were candidates for multivariate analysis. The candidate variables were gender, pre-ECMO creatinine level, transfusion history, and duration of ECMO support.

![The incidence of infection according to the duration of ECMO.\
ECMO = extracorporeal membrane oxygenation.](jkms-32-593-g001){#F1}

DISCUSSION
==========

We found that the incidence of nosocomial infection in an adult population undergoing ECMO was 43.3 cases per 1,000 ECMO-days. In multivariate analyses, both a higher preoperative creatinine level and the duration of ECMO support were independently associated with nosocomial infection. ECMO patients are at an increased risk for infections as a consequence of being in an ICU. Mechanical ventilators, central venous catheters, indwelling urinary catheters, surgical incisions, and health care providers are all sources of infection for ECMO patients. In general, the rate of nosocomial infection in the ICU has ranged from 13.9% to more than 44.0% ([@B12][@B13]).

In terms of the site of nosocomial infection, Vincent et al. ([@B12]) analyzed data from 1,417 ICUs in Europe to determine the incidence of pathogens and infections; pneumonia and other lower RTIs (64.7%) were the most common diseases, followed by UTI (17.6%) and BSI (12.0%). However, among infections during ECMO support, BSI was the most common, occurring in 32.6% to 89.4%, and BSIs were predominant in most studies, followed by RTIs, UTIs, and surgical site infections ([@B7][@B14][@B15]). In our study, the infection site differed from that of the general ECMO cohort. We found that the incidence of RTI was similar to that of BSI.

We found that the hazard ratio for nosocomial infection in patients with higher levels of preoperative creatinine was 2.176 (*P* = 0.033). Although the precise mechanism by which increased preoperative creatinine increases the risk of nosocomial infection remains unknown, some data suggest that increased serum levels of creatinine correlate with nosocomial infection. An increase in creatinine levels reflects the presence of kidney disease; an injured kidney may compromise the immune response via systemic release from leukocytes in the kidneys and renal tubular cells ([@B16][@B17][@B18][@B19][@B20]). Such changes in the host immune response may be associated with nosocomial infection.

We also found that the duration of ECMO was a risk factor for infection. Many previous studies showed that the duration of ECMO support was the most important risk factor of acquired infection during ECMO and was associated with a significantly increased rate of death ([@B7][@B14][@B15]). Burket et al. ([@B21]) reported that the rate of BSI increased with the duration of ECMO support. Among patients who underwent ECMO for 3--10 days, the rate of BSI was 9.5 cases per 1,000 ECMO-days, and among those who underwent ECMO for 11--20 days and 21--30 days, the rates of BSI increased to 27.2 cases per 1,000 ECMO-days and 64.5 cases per 1,000 ECMO-days, respectively. We found that a longer duration of ECMO was associated with nosocomial infection. The receiver operation characteristic (ROC) curve showed that a cut-off point of 3.7 days was significant. The incidence of nosocomial infection was higher in patients who underwent ECMO for \> 3.7 days than for shorter times. However, nosocomial infection did not affect survival to discharge. This may be because of our small patient numbers. Further studies on larger cohorts are required.

In terms of the causative microorganisms, large-scale international data show that *Staphylococcus aureus* and other *Staphylococcus* species (38%) are the most common pathogens causing BSIs, followed by *Escherichia coli* (24%), in critically ill patients without ECMO support ([@B12][@B22]). In addition, *Candida* species are often isolated in the ICU and can cause pneumonia and BSIs with a mortality rate of up to 47% ([@B12][@B22]). On the other hand, microbes are commonly associated with medical device-related infections in patients with ECMO support, such as coagulase-negative *Staphylococcus*, *Pseudomonas*, and *Candida* species ([@B7]). However, the balance is shifting from multi-resistant staphylococci to highly resistant classes of *A. baumannii* and *P. aeruginosa* ([@B23]). In our study, *A. baumannii* was the most common pathogen in both blood and the respiratory tract, which would be a common pathogen in the ICU environment. We encountered no case of fungal infection (for example, *Candida*) in the present study. This may have been due to the short duration of ECMO compared with those in other ECMO cohort studies.

This study had the limitations inherent in retrospective work using observational data from a single center. Although our patient numbers were too low to allow us to draw strong conclusions, we sought to identify precise risk factors in a homogeneous group.

A higher preoperative creatinine level and an extended duration of ECMO support were risk factors for nosocomial infection. Therefore, to avoid the development of nosocomial infections, strategies shortening the length of ECMO support should be applied whenever possible.
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